Streetbeat News

Regulatory

MOLN

Molecular Partners will present data from its ongoing Phase 1 trial of MP0317 monotherapy for patients with advanced solid tumors at the 2023 ASCO Meeting.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 9:04 pm

EFTR

eFFECTOR Therapeutics reported data updates from Phase 2 expansion cohorts evaluating Zotatifin in ER+ metastatic breast cancer patients at ASCO 2023. Partial responses were observed in 26% of evaluable patients treated with Zotatifin combined with fulvestrant and abemaciclib. The combinations were generally well tolerated.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 8:52 pm

COF

KEY

The New York City Banking Commission has voted to freeze NYC's deposits at Capital One (COF) and KeyBank, citing concerns over their Community Reinvestment Act (CRA) performance. The decision will impact the banks' ability to receive new deposits from the city.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 8:51 pm

HCM

TAK

Takeda (TAK) and HUTCHMED (HCM) announced that the FDA has granted priority review for their New Drug Application (NDA) for fruquintinib, a treatment for previously treated metastatic colorectal cancer. The Prescription Drug User Fee Act (PDUFA) goal date for the NDA is November 30, 2023.

Portfolio Pulse from Happy Mohamed

May 25, 2023 | 8:32 pm

ALKS

Alkermes has filed its definitive proxy statement with the SEC and issued a letter to shareholders regarding its 2023 Annual General Meeting, scheduled for June 29, 2023. Sarissa Capital Management intends to nominate three director candidates for election at the meeting.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 8:31 pm

HLI

Houlihan Lokey (HLI) agrees to a $15 million SEC settlement to resolve an investigation into its compliance with records preservation requirements related to off-channel electronic messaging platforms.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 8:27 pm

ARDS

Aridis Pharmaceuticals (NASDAQ:ARDS) received a notice from Nasdaq for not being in compliance with listing rules due to the late filing of its Form 10-Q for Q1 2023. The company is working to complete the filing and anticipates filing it as soon as possible.

Portfolio Pulse from Happy Mohamed

May 25, 2023 | 8:26 pm

UNAM

Unico American Corporation (NASDAQ:UNAM) received an additional notice from Nasdaq for not filing its Quarterly Report on Form 10-Q for the period ended March 31, 2023, resulting in noncompliance with Nasdaq Listing Rule 5250(c)(1). The company has 60 days to submit a plan to regain compliance.

Portfolio Pulse from Happy Mohamed

May 25, 2023 | 8:22 pm